Kura Oncology (KURA) Downgraded to “Sell” at Zacks Investment Research

Zacks Investment Research lowered shares of Kura Oncology (NASDAQ:KURA) from a hold rating to a sell rating in a research report report published on Wednesday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other research firms also recently weighed in on KURA. Wedbush began coverage on Kura Oncology in a research note on Tuesday, December 26th. They set a buy rating and a $19.00 price target on the stock. BidaskClub raised Kura Oncology from a sell rating to a hold rating in a research note on Friday, December 22nd. Oppenheimer set a $18.00 price target on Kura Oncology and gave the stock a buy rating in a research note on Thursday, November 16th. ValuEngine downgraded Kura Oncology from a hold rating to a sell rating in a research note on Friday, December 1st. Finally, Cann reaffirmed a buy rating and set a $17.50 price target on shares of Kura Oncology in a research note on Monday, December 11th. Three analysts have rated the stock with a sell rating and six have assigned a buy rating to the company. Kura Oncology has an average rating of Hold and an average target price of $18.08.

Kura Oncology (NASDAQ:KURA) traded up $0.40 during mid-day trading on Wednesday, reaching $16.05. The company had a trading volume of 133,729 shares, compared to its average volume of 179,598. Kura Oncology has a fifty-two week low of $5.78 and a fifty-two week high of $17.50. The company has a debt-to-equity ratio of 0.07, a quick ratio of 13.48 and a current ratio of 13.48.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings results on Tuesday, November 7th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.37) by ($0.01). equities research analysts forecast that Kura Oncology will post -1.52 earnings per share for the current year.

Institutional investors have recently modified their holdings of the company. State of Wisconsin Investment Board purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $102,000. Rhumbline Advisers purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $131,000. New York State Common Retirement Fund purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $142,000. OxFORD Asset Management LLP purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $217,000. Finally, Schwab Charles Investment Management Inc. purchased a new stake in shares of Kura Oncology in the second quarter worth approximately $226,000. 64.26% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This article was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and republished in violation of U.S. and international trademark and copyright legislation. The original version of this article can be accessed at https://www.dispatchtribunal.com/2018/01/14/kura-oncology-kura-downgraded-to-sell-at-zacks-investment-research.html.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply